Moore Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Moore Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,000	Closed	-$2.13M	–	517
2024 Q2	$2.13M	Buy	+20,000	New	+$2.2M	0.04%	267
2023 Q4	–	Sell	-6,100	Closed	-$790K	–	494
2023 Q3	$790K	Sell	6,100 -5,900	-49%	-$786K	0.01%	312
2023 Q2	$1.49M	Buy	12,000 +9,000	+300%	+$1.21M	0.03%	280
2023 Q1	$439K	Buy	+3,000	New	+$444K	0.01%	327
2022 Q3	–	Sell	-45,829	Closed	-$7.15M	–	720
2022 Q2	$7.15M	Sell	45,829 -114,771	-71%	-$17.7M	0.19%	126
2022 Q1	$25M	Buy	+160,600	New	+$23.3M	0.64%	26
2021 Q1	–	Sell	-169,449	Closed	-$28M	–	730
2020 Q4	$28M	Buy	169,449 +86,995	+106%	+$13M	0.31%	47
2020 Q3	$11.8M	Buy	+82,454	New	+$10.2M	0.22%	92
2016 Q1	–	Sell	-35,000	Closed	-$4.92M	–	287
2015 Q4	$4.92M	Buy	+35,000	New	+$4.85M	0.15%	143

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Moore Capital Management's JAZZ Position: Q3 2024 in Review

Moore Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 20,000 shares — an estimated $2.13M sold.

Moore Capital Management first reported a position in JAZZ in Q4 2015 and held it in 9 quarters. The position peaked at $28M in Q4 2020. 478 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

Moore Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Moore Capital Management sold 20,000 Jazz Pharmaceuticals shares in Q3 2024, an estimated $2.13M.
Moore Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 9 quarters.
Moore Capital Management's Jazz Pharmaceuticals position peaked at $28M in Q4 2020.
478 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.